APOE ε3 attenuates experimental autoimmune neuritis by modulating T cell, macrophage and Schwann cell functions

Experimental Neurology

Volumn 230, Issue 2, 2011, Pages 197-206

  Zhang, Hong Liang ^a   Mao, Xi Jing ^a   Zhang, Xing Mei ^a   Li, Hai Feng ^a,b   Zheng, Xiang Yu ^a   Adem, Abdu ^c   Mix, Eilhard ^d   Zhu, Jie ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b QINGDAO UNIVERSITY   (China)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apolipoprotein e; Experimental autoimmune neuritis; Macrophage; Nitric oxide; Schwann cell; T cell

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRIC OXIDE; PHYTOHEMAGGLUTININ; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE NEURITIS; GUILLAIN BARRE SYNDROME; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE FUNCTION; MALE; MOUSE; NEURITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHWANN CELL; SPLEEN WEIGHT; T LYMPHOCYTE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; APOLIPOPROTEIN E3; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; MACROPHAGES; MICE; MICE, TRANSGENIC; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; SCHWANN CELLS; SPLEEN; T-LYMPHOCYTES;

EID: 79958709822     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.04.016     Document Type: Article

References (35)

1. Ali K., Middleton M., Puré E., Rader D.J. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res. 2005, 97:922-927.
2. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 2003, 55:241-269.
3. Bocksch L., Stephens T., Lucas A., Singh B. Apolipoprotein E: possible therapeutic target for atherosclerosis. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2001, 1:93-106.
4. Chan W.C., White P.D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach 2000, Oxford University Press, Oxford-New York.
5. Colton C.A., Brown C., Cook D., Needham L., Xu Q., Czapiga M., et al. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol. Aging 2002, 23:777-785.
6. Conti G., Rostami A., Scarpini E., Baron P., Galimberti D., Bresolin N., et al. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Exp. Neurol. 2004, 187:350-358.
7. Duan R.S., Jin T., Yang X., Mix E., Adem A., Zhu J. Apolipoprotein E deficiency enhances the antigen-presenting capacity of Schwann cells. Glia 2007, 55:772-776.
8. Gerdes L.U. The common polymorphism of apolipoprotein E. Geographical aspects and new pathophysiological relations. Clin. Chem. Lab. Med. 2003, 41:628-631.
9. Gerdes L.U., Klausen I.C., Sihm I., Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet. Epidemiol. 1992, 9:155-167.
10. Getz G.S., Reardon C.A. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J. Lipid Res. 2009, 50:s156-s161.
11. Gold R., Archelos J.J., Hartung H.P. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol. 1999, 9:343-360.
12. Hahn A.F. Guillain-Barré syndrome. Lancet 1998, 352:635-641.
13. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
14. Kelly M.E., Clay M.A., Mistry M.J., Hsieh L.H., Harmony J.A. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell. Immunol. 1994, 159:124-139.
15. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
16. Koski C.L. Mechanisms of Schwann cell damage in inflammatory neuropathy. J. Infect. Dis. 1997, 176(Suppl 2):S169-S172.
17. Laskowitz D.T., Lee D.M., Schmechel D., Staats H.F. Altered immune responses in apolipoprotein E-deficient mice. J. Lipid Res. 2000, 41:613-620.
18. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariéty J., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
19. Lee J.M., Kim Y.J., Ra H., Kang S.J., Han S., Koh J.Y., Kim Y.H. The involvement of caspase-11 in TPEN-induced apoptosis. FEBS Lett. 2008, 582:1871-1876.
20. Maezawa I., Nivison M., Montine K.S., Maeda N., Montine T.J. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB 2006, 20:797-799.
21. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
22. Mao X.J., Zhang X.M., Zhang H.L., Quezada H.C., Mix E., Yang X., et al. TNF-alpha receptor 1 deficiency reduces antigen-presenting capacity of Schwann cells and ameliorates experimental autoimmune neuritis in mice. Neurosci. Lett. 2010, 470:19-23.
23. Meyer zu Hörste G., Hu W., Hartung H.P., Lehmann H.C., Kieseier B.C. The immunocompetence of Schwann cells. Muscle Nerve 2008, 37:3-13.
24. Osuga J., Yonemoto M., Yamada N., Shimano H., Yagyu H., Ohashi K., et al. Cholesterol lowering in low density lipoprotein receptor knockout mice overexpressing apolipoprotein E. J. Clin. Invest. 1998, 102:386-394.
25. Press R., Ozenci V., Kouwenhoven M., Link H. Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 2002, 58:476-478.
26. Pritchard J., Hughes R.A.C., Rees J.H., Willison H.J., Nicoll J.A.R. Apolipoprotein E genotypes and clinical outcome in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 2003, 74:971-973.
27. Rall S.C., Weisgraber K.H., Mahley R.W. Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 1982, 257:4171-4178.
28. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 2008, 28:11445-11453.
29. Sun Y., Wu S., Bu G., Onifade M.K., Patel S.N., LaDu M.J., et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 1998, 18:3261-3272.
30. Vitek M.P., Brown C.M., Colton C.A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 2009, 30:1350-1360.
31. Waksman B.H., Adams R.D. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J. Exp. Med. 1955, 102:213-236.
32. Yu S., Duan R.S., Chen Z., Quezada H.C., Bao L., Nennesmo I., et al. Increased susceptibility to experimental autoimmune neuritis after upregulation of the autoreactive T cell response to peripheral myelin antigen in apolipoprotein E-deficient mice. J. Neuropathol. Exp. Neurol. 2004, 63:120-128.
33. Zhang H.L., Wu J., Zhu J. The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis. J. Biomed. Biotechnol. 2010, 2010:357412.
34. Zhang H.L., Wu J., Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Dev. Immunol. 2010, 2010:186813.
35. Zhu J., Bai X.F., Mix E., Link H. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL12, TNF-alpha, TNF-beta and cytolysin. Clin. Immunol. Immunopathol. 1997, 84:85-94.